| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695093 | Gynecologic Oncology | 2017 | 5 Pages |
Abstract
The combination of everolimus and letrozole is associated with a promising 47% 12-week PFS rate in patients with ER-positive relapsed high-grade ovarian cancer with acceptable toxicity. PDX tumor models can be generated from biopsies of ovarian tumors.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Gerardo Colon-Otero, S. John Weroha, Nathan R. Foster, Paul Haluska, Xiaonan Hou, Andrea E. Wahner-Hendrickson, Aminah Jatoi, Matthew S. Block, Tri A. Dinh, Matthew W. Robertson, John A. Copland,